Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Donald F. Gleason"'
Publikováno v:
Journal of Urology. 199
Autor:
Gregory Bernstein, William A. See, Donald F. Gleason, Clive Morris, Jonathon Armstrong, David G. McLeod, Ira W. Klimberg, Gerald W. Chodak, James E. Montie
Publikováno v:
Journal of Urology. 176:75-80
We describe the results of North American Trial 23 of the bicalutamide (Casodex) early prostate cancer program in the context of the overall early prostate cancer program findings.In Trial 23, 3,292 men with T1b-4, N0-Nx (N+ not allowed) M0 prostate
Autor:
Horst Zincke, Erik J. Bergstralh, Michael J. Barry, Steven J. Jacobsen, Richard S. Cox, Michael L. Blute, Donald F. Gleason M.D., Malcolm A. Bagshaw, Peter C. Albertsen, Richard G. Middleton
Publikováno v:
Cancer. 91:2302-2314
BACKGROUND With a lack of data from randomized trials, the optimal management of men with nonmetastatic prostate carcinoma is controversial. The authors sought to define the outcomes of three common strategies for managing patients with nonmetastatic
Autor:
Noell Stone, Frank D. Gilliland, Linda C. Harlan, Donald F. Gleason, Charles R. Key, William C. Hunt
Publikováno v:
The Journal of Urology. :846-850
Purpose: During the 1980s and 1990s the number, incidence rate and proportion of moderately differentiated prostate cancer cases ascertained by population based cancer registries increased substantially. The increase is thought to have resulted from
Autor:
Pratap K. Reddy, Michael J. Wilson, Akhouri A. Sinha, Bonnie F. Sloane, Donald F. Gleason, Barry J. Quast
Publikováno v:
The Anatomical Record. 252:281-289
Cathepsin B (CB) is involved in invasion and metastasis of a variety of solid organ tumors, including human prostate cancer. The tertiary structures of the proenzyme and mature forms of CB are related closely, as revealed by crystallographic studies.
Autor:
Onofrea F. Deleon, Akhouri A. Sinha, Donald F. Gleason, James L. Sackrison, Michael J. Wilson
Publikováno v:
The Anatomical Record. 245:652-661
Background Adenocarcinoma of the prostate (CaP) is the second highest cause of cancer deaths in U.S. males. Current chemotherapeutic and/or endocrine treatments do not specifically and selectively target tumor cells of prostate cancer and benign pros
Autor:
Yousuf Sharief, Isabell A. Sesterhenn, Jonathan I. Epstein, Robert L. Becker, Alan W. Partin, Donald S. Coffey, Donald F. Gleason, Ulrika V. Mikel, James L. Mohler, F. Kash Mostofi
Publikováno v:
Cancer. 69:511-519
Carcinoma is found unexpectedly in approximately 10% or more of the 400,000 prostatectomies performed annually in the United States. Patients with Stage A2 carcinoma die of their disease in only 35% of the cases. To alter the course of disease in the
Autor:
Gerald W. Chodak, William A. See, Donald F. Gleason, Karl P.J. Delaere, Kevin Carroll, C.J. Tyrrell, Peter Iversen, James E. Montie, David G. McLeod, D. M. A. Wallace, Ira W. Klimberg, Jan-Erik Johansson, P. E. R. Lundmo, Teuvo L.J. Tammela, Thomas Morris, Manfred P. Wirth
Publikováno v:
Urology. 63(5)
Objectives To report an exploratory subgroup analysis assessing the extent to which the overall benefit found in the Early Prostate Cancer program is dependent on lymph node status at randomization. The program is ongoing, and the overall survival da
Autor:
Donald F, Gleason, George T, Mellinger
Publikováno v:
The Journal of urology. 167(2 Pt 2)
Autor:
Donald F. Gleason, David G. McLeod, Kevin M. Tomera, Nick Fotheringham, Marilyn Campion, Norman Zinner, Marc B. Garnick
Publikováno v:
Urology. 58(5)
Objectives. To evaluate the levels of testosterone and other hormones in men with prostate cancer treated with abarelix versus leuprolide acetate. Methods. Patients (n = 269) were randomized to receive open-label abarelix 100 mg or leuprolide acetate